Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 with GFS202A or GFH276 vs GFH375 monotherapy in KRAS G12D-mutant pretreated unresectable or metastatic pancreatic cancer
CTR20262980Phase 2Active
- Sponsor
- GenFleet Therapeutics
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH375 in pancreatic cancer (PC), sponsored by GenFleet Therapeutics. Started Aug 2026; status: active.
02
Drugs
GFH375
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20262980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262980.